Dietary lipids and their oxidized products in Alzheimer's disease

Molecular Nutrition and Food Research

Volumn 55, Issue SUPPL. 2, 2011, Pages S161-SS172

  Corsinovi, Laura ^a,b   Biasi, Fiorella ^b   Poli, Giuseppe ^b   Leonarduzzi, Gabriella ^b   Isaia, Gianluca ^b  

^a CARDINAL MASSAIA HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Alzheimer's Disease; Cholesterol; Lipid oxidation products; Nutrition; PUFA

Indexed keywords

ANIMALIA;

EID: 80053291126     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201100208     Document Type: Review

References (132)

1. Hazzard, W. R., Blass, J. P., Halter, J. B., Ouslander, J. G., Tinetti, M. E., Principles of Geriatric Medicine and Gerontology, 5th Edn., McGraw-Hill, New York 2003.
2. Selkoe, D. J., Defining molecular targets to prevent Alzheimer disease. Arch. Neurol. 2005, 62, 192-195.
3. Puglielli, L., Tanzi, R. E., Kovacs, D. M., Alzheimer's disease: the cholesterol connection. Nat. Neurosci. 2003, 6, 345-351.
4. Wenk, G. L., Neuropathologic changes in Alzheimer's disease. J. Clin. Psychiatry 2003, 64, 7-10.
5. Björkhem, I., Cedazo-Minguez, A., Leoni, V., Meaney, S., Oxysterols and neurodegenerative diseases. Mol. Aspects Med. 2009, 30, 171-179.
6. Whelan, J., (n-6) And (n-3) polyunsaturated fatty acids and the aging brain: food for thought. J. Nutr. 2008, 138, 2521-2522.
7. Jicha, G. A., Markesber, W. R., Omega-3 fatty acids: potential role in the management of early Alzheimer's disease. Clin. Interv. Aging 2010, 5, 45-61.
8. Perez, S. E., Berg, B. M., Moore, K. A., He, B. et al., DHA diet reduces AD pathology in young APPswe/PS1DeltaE9 transgenic mice: Possible gender effects. J. Neurosci. Res. 2010, 88, 1026-1040.
9. Samieri, C., Féart, C., Letenneur, L., Dartigues, J. F. et al., Low plasma eicosapentaenoic acid and depressive symptomatology are independent predictors of dementia risk. Am. J. Clin. Nutr. 2008, 88, 714-721.
10. Su, H. M., Mechanisms of n-3 fatty acid-mediated development and maintenance of learning memory performance. J. Nutr. Biochem. 2010, 21, 364-373.
11. Bowman, G. L., Dodge, H., Frei, B., Calabrese, C. et al., Ascorbic acid and rates of cognitive decline in Alzheimer's disease. J. Alzheimers Dis. 2009, 16, 93-98.
12. Harrison, F. E., Hosseini, A. H., McDonald, M. P., May, J. M., Vitamin C reduces spatial learning deficits in middle-aged and very old APP/PSEN1 transgenic and wild-type mice. Pharmacol. Biochem. Behav. 2009, 93, 443-450.
13. Usoro, O. B., Mousa, S. A., Vitamin E forms in Alzheimer's disease: a review of controversial and clinical experiences. Crit. Rev. Food Sci. Nutr. 2010, 50, 414-419.
14. Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M. et al., The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325, 733-736.
15. Younkin, S. G., Processing of the Alzheimer's disease beta A4 amyloid protein precursor (APP). Brain Pathol. 1991, 1, 253-262.
16. Kojro, E., Fahrenholz, F., The non-amyloidogenic pathway: structure and function of alpha-secretases. Subcell Biochem. 2005, 38, 105-127.
17. Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S. et al., Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286, 735-741.
18. Steiner, H., Winkler, E., Edbauer, D., Prokop, S. et al., PEN-2 is an integral component of the gammasecretase complex required for coordinated expression of presenilin and nicastrin. J. Biol. Chem. 2002, 277, 39062-39065.
19. Yu, G., Nishimura, M., Arawaka, S., Levitan, D. et al., Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and [beta] APP processing. Nature 2000, 407, 48-54.
20. Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H. et al., Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994, 13, 45-53.
21. Kuhn, P. H., Wang, H., Dislich, B., Colombo, A. et al., ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J. 2010, 29, 3020-3032.
22. Supnet, C., Bezprozvanny, I., Neuronal calcium signaling, mitochondrial dysfunction, and Alzheimer's disease. J. Alzheimers Dis. 2010, 20, S487-S98.
23. Parvathy, S., Rajadas, J., Ryan, H., Vaziri, S. et al., Abeta peptide conformation determines uptake and interleukin-1 alpha expression by primary microglial cells. Neurobiol. Aging 2009, 30, 792-804.
24. Tillement, L., Lecanu, L., Papadopoulos, V., Alzheimer's disease: effects of β-amyloid on mitochondria. Mitochondrion 2011, 11, 13-21.
25. Fiala, M., Veerhuis, R., Biomarkers of inflammation and amyloid-beta phagocytosis in patients at risk of Alzheimer disease. Exp. Gerontol. 2010, 45, 57-63.
26. Dries, D. R., Yu, G., Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer's disease. Curr. Alzheimer Res. 2008, 5, 132-146.
27. Sannerud, R., Annaert, W., Trafficking, a key player in regulated intramembrane proteolysis. Semin. Cell Dev. Biol. 2009, 20, 183-190.
28. Mazza, M., Pomponi, M., Janiri, L., Bria, P., Mazza, S., Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: an overview. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31, 12-26.
29. van der Beek, E. M., Kamphuis, P. J., The potential role of nutritional components in the management of Alzheimer's Disease. Eur. J. Pharmacol. 2008, 585, 197-207.
30. Rothman, S. M., Mattson, M. P., Adverse stress, hippocampal networks, and Alzheimer's disease. Neuromol. Med. 2010, 12, 56-70
31. Lee, H. P., Zhu, X., Casadesus, G., Castellani, R. J. et al., Antioxidant approaches for the treatment of Alzheimer's disease. Exp. Rev. Neurother. 2010, 10, 1201-1208.
32. Farooqui, A. A., Horrocks, L. A., Farooqui, T., Modulation of inflammation in brain: a matter of fat. J. Neurochem. 2007, 101, 577-599.
33. Akiyama, H., Barger, S., Barnum, S., Bradt, B. et al., Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21, 383-421.
34. Sottero, B., Gamba, P., Gargiulo, S., Leonarduzzi, G., Poli, G., Cholesterol oxidation products and disease: an emerging topic of interest in medicinal chemistry. Curr. Med. Chem. 2009, 16, 685-705.
35. Otaegui-Arrazola, A., Menéndez-Carreño, M., Ansorena, D., Astiasarán, I., Oxysterols: a world to explore. Food Chem. Toxicol. 2010, 48, 3289-3303.
36. Prasanthi, J. R., Huls, A., Thomasson, S., Thompson, A. et al., Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on beta-amyloid precursor protein levels and processing in human neuroblastoma SH-SY5Y cells. Mol. Neurodegener. 2009, 4, 1.
37. Famer, D., Meaney, S., Mousavi, M., Nordberg, A. et al., Regulation of alpha- and beta-secretase activity by oxysterols: cerebrosterol stimulates processing of APP via the alpha-secretase pathway. Biochem. Biophys. Res. Commun. 2007, 359, 46-50.
38. Van Duijn, C. M., Clayton, D. G., Chandra, V., Fratiglioni, L. et al., Interaction between genetic and environmental risk factors for Alzheimer's disease: a reanalysis of case-control studies. EURODEM risk factors research group. Genet. Epidemiol. 1994, 11, 539-551.
39. Tanzi, R. E., Bertram, L., New frontiers in Alzheimer's disease genetics. Neuron 2001, 32, 181-184.
40. Saitoh, T., Xia, Y., Chen, X., Masliah, E. et al., The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. Ann. Neurol. 1995, 37, 110-112.
41. van Duijn, C. M., Cruts, M., Theuns, J., Van Gassen, G. et al., Genetic association of the presenilin-1 regulatory region with early-onset Alzheimer's disease in a population-based sample. Eur. J. Hum. Genet. 1999, 7, 801-806.
42. Corder, E., Saunders, A., Strittmatter, W., Schmechel, D. et al., Gene dose of apolipoprotein apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261, 921-923.
43. Laskowitz, D. T., Horsburgh, K., Roses, A. D., Apolipoprotein E and the CNS response to injury. J. Cereb. Blood Flow Metab. 1998, 18, 465-471.
44. Poirier, J., Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci. 1994, 17, 525-530.
45. Gee, J. R., Keller, J. N., Astrocytes: regulation of brain homeostasis via apolipoprotein E. Int. J. Biochem. Cell Biol. 2005, 37, 1145-1150.
46. Holtzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M. et al., Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2000, 97, 2892-2897.
47. Castaño, E. M., Prelli, F. C., Frangione, B., Apolipoprotein E and amyloidogenesis. Lab. Invest. 1995, 73, 457-460.
48. Luchsinger, J. A., Mayeux, R., Dietary factors and Alzheimer's disease. Lancet Neurol. 2004, 3, 579-587.
49. Scarmeas, N., Stern, Y., Tang, M. X., Mayeux, R., Luchsinger, J. A., Mediterranean diet and risk for Alzheimer's disease. Ann. Neurol. 2006, 59, 912-921.
50. Chen, C. T., Green, J. T., Orr, S. K., Bazinet, R. P., Regulation of brain polyunsaturated fatty acid uptake and turnover. Prostaglandins Leukot. Essent. Fatty Acids 2008, 79, 85-91.
51. Rapoport, S. I., Brain arachidonic and docosahexaenoic acid cascades are selectively altered by drugs, diet and disease. Prostaglandins Leukot. Essent. Fatty Acids 2008, 79, 153-156.
52. Florent-Béchard, S., Desbéne, C., Garcia, P., Allouche, A. et al., The essential role of lipids in Alzheimer's disease. Biochimie 2009, 91, 804-809.
53. Montine, T. J., Morrow, J. D., Fatty acid oxidation in the pathogenesis of Alzheimer's disease. Am. J. Pathol. 2005, 166, 1283-1289.
54. Hama, H., Hara, C., Yamaguchi, K., Miyawaki, A., PKC signaling mediates global enhancement of excitatory synaptogenesis in neurons triggered by local contact with astrocytes. Neuron 2004, 41, 405-415.
55. Söderberg, M., Edlund, C., Kristensson, K., Dallner, G., Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 1991, 26, 421-425.
56. Tassoni, D., Kaur, G., Weisinger, R. S., Sinclair, A. J., The role of eicosanoids in the brain. Asia Pac. J. Clin. Nutr. 2008, 17, 220-228.
57. Freeman, M. P., Hibbeln, J. R., Wisner, K. L., Davis, J. M. et al., Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J. Clin. Psychiatry 2006, 67, 1954-1967.
58. Calon, F., Lim, G. P., Morihara, T., Yang, F. et al., Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. Eur. J. Neurosci. 2005, 22, 617-626.
59. Muskiet, F. A., Fokkema, M. R., Schaafsma, A., Boersma, E. R., Crawford, M. A., Is docosahexaenoic acid (DHA) essential? Lessons from DHA status regulation, our ancient diet, epidemiology and randomized controlled trials. J. Nutr. 2004, 134, 183-186.
60. Igarashi, M., DeMar, J. C., Jr, Ma, K., Chang, L. et al., Docosahexaenoic acid synthesis from alpha-linolenic acid by rat brain is unaffected by dietary n-3 PUFA deprivation. J. Lipid Res. 2007, 48, 1150-1158.
61. Boudrault, C., Bazinet, R. P., Ma, D. W., Experimental models and mechanisms underlying the protective effects of n-3 polyunsaturated fatty acids in Alzheimer's disease. J. Nutr. Biochem. 2009, 20, 1-10.
62. Babenko, N. A., Semenova, Y. A., Effects of long-term fish oil-enriched diet on the sphingolipid metabolism in brain of old rats. Exp. Gerontol. 2010, 45, 375-380.
63. Freemantle, E., Vandal, M., Tremblay-Mercier, J., Tremblay, S. et al., Omega-3 fatty acids, energy substrates, and brain function during aging. Prostaglandins Leukot. Essent. Fatty Acids 2006, 75, 213-220.
64. Wortman, P., Miyazaki, Y., Kalupahana, N. S., Kim, S. et al., n3 and n6 polyunsaturated fatty acids differentially modulate prostaglandin E secretion but not markers of lipogenesis in adipocytes. Nutr. Metab. (Lond.) 2009, 6, 5.
65. Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C. et al., Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch. Neurol. 2003, 60, 940-946.
66. Hashimoto, M., Hossain, S., Shimada, T., Sugioka, K. et al., Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. J. Neurochem. 2002, 81, 1084-1091.
67. Lim, G. P., Calon, F., Morihara, T., Yang, F. et al., A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged alzheimer mouse model. J. Neurosci. 2005, 25, 3032-3040.
68. Ma, Q. L., Teter, B., Ubeda, O. J., Morihara, T. et al., Omega-3 fatty acid docosahexaenoic acid increases SorLA/LR11, a sorting protein with reduced expression in sporadic Alzheimer's disease (AD): relevance to AD prevention. J. Neurosci. 2007, 27, 14299-14307.
69. Rogaeva, E., Meng, Y., Lee, J. H., Gu, Y., Kawarai, T. et al., The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 2007, 39, 168-177.
70. Kawarabayashi, T., Shoji, M., Younkin, L. H., Wen-Lang, L. et al., Dimeric amyloid β protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 2004, 24, 3801-3809.
71. Grimm, M. O., Kuchenbecker, J., Grösgen, S., Burg, V. K. et al., Docosahexaenoic acid reduces amyloid beta production via multiple pleiotropic mechanisms. J. Biol. Chem. 2011, 286, 14028-14039.
72. Calon, F., Lim, G. P., Yang, F., Morihara, T. et al., Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004, 43, 633-645.
73. Calon, F., Cole, G., Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. Prostaglandins Leukot. Essent. Fatty Acids 2007, 77, 287-293.
74. Bazan, N. G., Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol. 2005, 15, 159-166.
75. Bazan, N. G., Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease. J. Lipid Res. 2009, 50, S400-S405.
76. Arendash, G. W., Jensen, M. T., Salem, N., Hussein, N. et al., A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer's transgenic mice. Neuroscience 2007, 149, 286-302.
77. Kröger, E., Verreault, R., Carmichael, P. H., Lindsay, J. et al., Omega-3 fatty acids and risk of dementia: the Canadian Study of Health and Aging. Am. J. Clin. Nutr. 2009, 90, 184-192.
78. Engelhart, M. J., Geerlings, M. I., Ruitenberg, A., Van Swieten, J. C. et al., Diet and risk of dementia: does fat matter?: the Rotterdam Study. Neurology 2002, 59, 1915-1921.
79. Barberger-Gateau, P., Letenneur, L., Deschamps, V., Peres, K. et al., Fish, meat, and risk of dementia: cohort study. Br. Med. J. 2002, 325, 932-933.
80. Schaefer, E. J., Bongard, V., Beiser, A. S., Lamon-Fava, S. et al., Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch. Neurol. 2006, 63, 1545-1550.
81. Kotani, S., Sakaguchi, E., Warashina, S., Matsukawa, N. et al., Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci. Res. 2006, 56, 159-164.
82. Freund-Levi, Y., Eriksdotter-Jönhagen, M., Cederholm, T., Basun, H. et al., Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch. Neurol. 2006, 63, 1402-1408.
83. Esterbauer, H., Schaur, R. J., Zollner, H., Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 1991, 11, 81-128.
84. Schneider, C., Porter, N. A., Brash, A. R., Routes to 4-hydroxynonenal: fundamental issues in the mechanisms of lipid peroxidation. J. Biol. Chem. 2008, 283, 15539-15543.
85. Riahi, Y., Cohen, G., Shamni, O., Sasson, S., Signaling and cytotoxic functions of 4-hydroxyalkenals. Am. J. Physiol. Endocrinol. Metab. 2010, 299, E879-E886.
86. Spickett, C. M., Wiswedel, I., Siems, W., Zarkovic, K., Zarkovic, N., Advances in methods for the determination of biologically relevant lipid peroxidation products. Free Radic. Res. 2010, 44, 1172-1202.
87. Babusikova, E., Hatok, J., Dobrota, D., Kaplan, P., Age-related oxidative modifications of proteins and lipids in rat brain. Neurochem. Res. 2007, 32, 1351-1356.
88. Negre-Salvayre, A., Auge, N., Ayala, V., Basaga, H. et al., Pathological aspects of lipid peroxidation. Free Radic. Res. 2010, 44, 1125-1171.
89. Singh, M., Nam, D. T., Arseneault, M., Ramassamy, C., Role of by-products of lipid oxidation in Alzheimer's disease brain: a focus on acrolein. J. Alzheimers Dis. 2010, 21, 741-756.
90. Praticò, D., The neurobiology of isoprostanes and Alzheimer's disease. Biochim. Biophys. Acta 2010, 1801, 930-933.
91. Markesbery, W. R., Kryscio, R. J., Lovell, M. A., Morrow, J. D., Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann. Neurol. 2005, 58, 730-735.
92. Mufson, E. J., Leurgans, S., Inability of plasma and urine F2A-isoprostane levels to differentiate mild cognitive impairment from Alzheimer's disease. Neurodegener. Dis. 2010, 7, 139-142.
93. Praticò, D., Lipid peroxidation and the aging process. Sci. Aging Knowledge Environ. 2002, re5.
94. Greilberger, J., Koidl, C., Greilberger, M., Lamprecht, M. et al., Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease. Free Radic. Res. 2008, 42, 633-638.
95. Nam, D.T., Arseneault, M., Zarkovic, N., Waeg, G., Ramassamy, C., Molecular regulations induced by acrolein in neuroblastoma SK-N-SH cells: relevance to Alzheimer's disease. J. Alzheimers Dis. 2010, 21, 1197-1216.
96. Bradley, M. A., Markesbery, W. R., Lovell, M. A., Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease. Free Radic. Biol. Med. 2010, 48, 1570-1576.
97. Bacot, S., Bernoud-Hubac, N., Baddas, N., Chantegrel, B. et al., Covalent binding of hydroxy-alkenals 4-HDDE, 4-HHE, and 4-HNE to ethanolamine phospholipid subclasses. J. Lipid Res. 2003, 44, 917-926.
98. Selley, M. L., Close, D. R., Stern, S. E., The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol. Aging 2002, 23, 383-388.
99. Poli, G., Schaur, R. J., Siems, W. G., Leonarduzzi, G., 4-hydroxynonenal: a membrane lipid oxidation product of medicinal interest. Med. Res. Rev. 2008, 28, 569-631.
100. Butterfield, D. A., Bader Lange, M. L., Sultana, R., Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim. Biophys. Acta 2010, 1801, 924-929.
101. Wang, D. S., Dickson, D. W., Malter, J. S., Beta-amyloid degradation and Alzheimer's disease. J. Biomed. Biotechnol. 2006, 3, 58406.
102. Wang, R., Wang, S., Malter, J. S., Wang, D. S., Effects of HNE-modification induced by Aβ on neprilysin expression and activity in SH-SY5Y cells. J. Neurochem. 2009, 108, 1072-1082.
103. Siegel, J. S., Bieschke, J., Powers, E. T., Kelly, J. W., The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. Biochemistry 2007, 46, 1503-1510.
104. Tamagno, E., Bardini, P., Obbili, A., Vitali, A. et al., Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol. Dis. 2002, 10, 279-288.
105. Guglielmotto, M., Giliberto, L., Tamagno, E., Tabaton, M., Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors. Front. Aging Neurosci. 2010, 9, 2-3.
106. Guichardant, M., Bacot, S., Molière, P., Lagarde, M., Hydroxy-alkenals from the peroxidation of n-3 and n-6 fatty acids and urinary metabolites. Prostaglandins Leukot. Essent. Fatty Acids 2006, 75, 179-182.
107. Bradley, M. A., Xiong-Fister, S., Markesbery, W. R., Lovell, M. A., Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression. Neurobiol. Aging 2010, DOI: 10.1016/j.neurobiolaging.2010.08.016.
108. Dietschy, J. M., Turley, S. D., Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 2001, 12, 105-112.
109. Lütjohann, D., Breuer, O., Ahlborg, G., Nennesmo, I. et al., Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc. Natl. Acad. Sci. USA 1996, 93, 9799-9804.
110. Björkhem, I., Meaney, S., Brain cholesterol: long secret life behind a barrier. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 806-815.
111. Björkhem, I., Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. J. Intern. Med. 2006, 260, 493-508.
112. Heverin, M., Meaney, S., Lütjohann, D., Diczfalusy, U. et al., Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J. Lipid Res. 2005, 46, 1047-1052.
113. Panza, F., Capurso, C., D'Introno, A., Colacicco, A. M. et al., Total cholesterol levels and the risk of mild cognitive impairment and Alzheimer's disease. J. Am. Geriatr. Soc. 2007, 55, 133-135.
114. Bertolotti, M., Del Puppo, M., Corna, F., Anzivino, C. et al., Increased appearance rate of 27-hydroxycholesterol in vivo in hypercholesterolemia: a possible compensatory mechanism. Nutr. Metab. Cardiovasc. Dis. 2011, DOI: 10.1016/j.numecd.2011.02.009.
115. Brown, J., 3rd, Theisler, C., Silberman, S., Magnuson, D. et al., Differential expression of cholesterol hydroxylases in Alzheimer's disease. J. Biol. Chem. 2004, 279, 34674-34681.
116. Gamba, P., Leonarduzzi, G., Tamagno, E., Guglielmotto, M. et al., Interaction between 24-hydroxycholesterol, oxidative stress, and amyloid-β in amplifying neuronal damage in Alzheimer's disease: three partners in crime. Aging Cell 2011, 10, 403-417.
117. Cordy, J. M., Hussain, I., Dingwall, C., Hooper, N. M., Turner, A. J., Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. USA 2003, 100, 11735-11740.
118. Gylys, K. H., Fein, J. A., Yang, F., Miller, C. A., Cole, G. M., Increased cholesterol in Abeta-positive nerve terminals from Alzheimer's disease cortex. Neurobiol. Aging 2007, 28, 8-17.
119. Simons, M., Keller, P., De Strooper, B., Beyreuther, K. et al., Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA 1998, 95, 6460-6464.
120. Sioen, I. A., Pynaert, I., Matthys, C., De Backer, G. et al., Dietary intakes and food sources of fatty acids for Belgian women, focused on n-6 and n-3 polyunsaturated fatty acids. Lipids 2006, 41, 415-422.
121. Kris-Etherton, P. M., Grieger, J. A., Etherton, T. D., Dietary reference intakes for DHA and EPA. Prostaglandins Leukot. Essent. Fatty Acids 2009, 81, 99-104.
122. Pasinetti, G. M., Eberstein, J. A., Metabolic syndrome and the role of dietary lifestyles in Alzheimer's disease. J. Neurochem. 2008, 106, 1503-1514.
123. Solfrizzi, V., Frisardi, V., Capurso, C., D'Introno, A. et al., Dietary fatty acids in dementia and predementia syndromes: epidemiological evidence and possible underlying mechanisms. Ageing Res. Rev. 2010, 9, 184-199.
124. Dangour, A. D., Allen, E., Elbourne, D., Fletcher, A. et al., Fish consumption and cognitive function among older people in the UK: baseline data from the Opal Study. J. Nutr. Health Aging 2009, 13, 198-202.
125. Poli, G., Sottero, B., Gargiulo, S., Leonarduzzi, G., Cholesterol oxidation products in the vascular remodeling due to atherosclerosis. Mol. Aspects Med. 2009, 30, 180-189.
126. Leonarduzzi, G., Gamba, P., Sottero, B., Kadl, A. et al., Oxysterol-induced up-regulation of MCP-1 expression and synthesis in macrophage cells. Free Radic. Biol. Med. 2005 39, 1152-1161.
127. Checkoway, H., Powers, K., Smith-Weller, T., Franklin, G. M. et al., Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am. J. Epidemiol. 2002, 155, 732-738.
128. Lindsay, J., Laurin, D., Verreault, R., Hébert, R. et al., Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am. J. Epidemiol. 2002, 156, 445-453.
129. Scarmeas, N., Stern, Y., Tang, M. X., Mayeux, R., Luchsinger, J. A., Mediterranean diet and risk for Alzheimer's disease. Ann. Neurol. 2006, 59, 912-921.
130. Youdim, K. A., Dobbie, M. S., Kuhnle, G., Proteggente, A. R. et al., Interaction between flavonoids and the blood-brain barrier: in vitro studies. J. Neurochem. 2003, 85, 180-192.
131. Lin, J. H., Yamazaki, M., Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 2003, 42, 59-98.
132. Williams, R. J., Spencer, J. P., Rice-Evans, C., Flavonoids: antioxidants or signalling molecules? Free Radic. Biol. Med. 2004, 36, 838-849.